Patent SG-11201909730P-A (SG)
Title: Bicyclic compounds and their use in the treatment of cancer
Inventor: BRAVO YALDA
IPC: C07D471/04
Filed: 2018-04-17
Abstract: WO 18/ 195 123 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 October 2018 (25.10.2018) WIPO I PCT omit IIl °nolo mu IOII Oil mono oimIE (10) International Publication Number WO 2018/195123 Al (51) International Patent Classification: C07D 209/08 (2006.01) A61P 35/00 (2006.01) CO7D 231/56 (2006.01) A61K 31/404 (2006.01) CO7D 235/06 (2006.01) A61K 31/416 (2006.01) CO7D 401/10 (2006.01) A61K 31/4184 (2006.01) CO7D 403/12 (2006.01) A61K 31/437 (2006.01) CO7D 471/04 (2006.01) (21) International Application Number: PCT/US2018/028034 (22) International Filing Date: 17 April 2018 (17.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/486,765 18 April 2017 (18.04.2017) US (71) Applicant: TEMPEST THERAPEUTICS, INC. [US/US]; One Sansome Street, Suite 3690, San Francisco, California 94104 (US). (72) Inventors: BRAVO, Yalda; One Sansome Street, Suite 3690, San Francisco, California 94104 (US). BURCH, Ja- son David; One Sansome Street, Suite 3690, San Francisco, California 94104 (US). CHEN, Austin Chih-Yu; One San- some Street, Suite 3690, San Francisco, California 94104 (US). NAGAMIZO, Joe Fred; One Sansome Street, Suite 3690, San Francisco, California 94104 (US). (74) Agent: SMITH, Deborah M.; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER (57) : The present disclosure is directed to novel compounds of Formula I and phar- maceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcino- ma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The com- pounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.